RESUMO
Imatinib inhibits Bcr-Abl, c-KIT and PDGFR kinases. It is approved for the treatment of chronic myeloid leukemia [CML], gastrointestinal stromal tumors [GIST] and has further therapeutic potential. Male ICR mice were given imatinib PO [50 or 25 mg/kg, 5 doses every 2 h]; euthanized 2 h after the last dose administration; plasma, liver, brain, spleen and kidney were collected and imatinib concentration measured by an optimized HPLC method for quantification in tissues. Methanol [1:1 v/v plasma] and pH 4, 40:30:30 [v/v/v] water-methanol-acetonitrile at 5 ml/g [brain] and 10 ml/g [spleen, kidney, liver] ratio was added to the samples, homogenized, sonicated, centrifuged [15, 000 rpm, 5 min, 2°C] and the supernatant injected into an Inertsil CN-3 column [4.6 mm x 150 mm, 5 micro m] using 64:35:1 [v/v/v] water-methanol-triethylamine [pH 4.8], flow rate 1 ml/min, 25°C. Imatinib eluted at 7.5 min [268 nm]. Linearity: 0.1-50 micro g/ml; precision, accuracy, inter- and intra-day variability was within 15%. Recovery was above 95% [plasma], 80% [brain] and 90% [kidney, liver, spleen]. Imatinib tissue concentrations were 6-8 folds higher than plasma except brain, where the ratio decreased from 0.24 to 0.08 suggesting limited brain penetration, likely due to blood brain barrier efflux transporters. The extensive distribution supports the expansion of therapeutic applications